Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia

EFFECTS OF CHANGES IN FAT, FISH, AND FIBRE INTAKES ON DEATH AND MYOCARDIAL REINFARCTION: DIET AND REINFARCTION TRIAL (DART)

Burr, M. L., Gilbert, J. F., Holliday, R. M., Elwood, P. C., Fehily, A. M., Rogers, S., Sweetnam, P. M., & Deadman, N. M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90828-3 · Cited by 2,610 · see citing works

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis

Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516 · see citing works

Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

GISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350 · see citing works

n-3 fatty acids and serum lipoproteins: human studies

Harris, W. (1997) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/65.5.1645s · Cited by 1,243 · see citing works

N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials.

Bucher, H. C., Hengstler, P., Schindler, C., & Meier, G. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01114-7 · Cited by 823 · see citing works

Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial

Otvos, J. D., Collins, D. E., Freedman, D. S., SHALAUROVA, I. Y., Schaefer, E. J., McNamara, J. R., Bloomfield, H. E., & Robins, S. J. (2006) · Circulation · doi:10.1161/circulationaha.105.565135 · Cited by 542 · see citing works

Regulation of Plasma Triglycerides in Insulin Resistance and Diabetes

Ginsberg, H. N., Zhang, Y.-L., & Hernandez-Ono, A. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.01.005 · Cited by 531 · see citing works

VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial

Sacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490 · see citing works

LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management

Cromwell, W. C., Otvos, J. D., Keyes, M. J., Pencina, M. J., SULLIVAN, L. M., Vasan, R. S., Wilson, P. W. F., & D’Agostino, R. B. (2007) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.10.001 · Cited by 428 · see citing works

Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels

Nakajima, K., SAITO, T., Tamura, A., Suzuki, M., Nakano, T., Adachi, M., Tanaka, A., Tada, N., Nakamura, H., Campos, E. M., et al. (1993) · Clinica Chimica Acta · doi:10.1016/0009-8981(93)90062-9 · Cited by 417 · see citing works

Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study

Davidson, M. H., Stein, E. A., Bays, H. E., Maki, K. C., Doyle, R. T., Shalwitz, R. A., Ballantyne, C. M., & Ginsberg, H. N. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.018 · Cited by 385 · see citing works

Lipoprotein-Associated Phospholipase A 2 Adds to Risk Prediction of Incident Coronary Events by C-Reactive Protein in Apparently Healthy Middle-Aged Men From the General Population

Köenig, W., Khuseyinova, N., Löwel, H., Trischler, G., & Meisinger, C. (2004) · Circulation · doi:10.1161/01.cir.0000143377.53389.c8 · Cited by 309 · see citing works

Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease

Liu, J., Sempos, C. T., Donahue, R. P., Dorn, J., Trevisan, M., & Grundy, S. M. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.06.032 · Cited by 277 · see citing works

Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and Implications for Treatment Under the Recent NCEP Writing Group Recommendations

Davidson, M. H., Maki, K. C., Pearson, T. A., Pasternak, R. C., Deedwania, P. C., McKenney, J. M., Fonarow, G. C., Maron, D. J., Ansell, B. J., Clark, L. T., et al. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.04.019 · Cited by 270 · see citing works

Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease

CASLAKE, M. J., Packard, C. J., Suckling, K. E., Holmes, S. D., Chamberlain, P., & Macphee, C. H. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00406-2 · Cited by 262 · see citing works

Lipoprotein-Associated Phospholipase A

Krumholz, H. (2001) · Journal watch · doi:10.1056/jc200101050000008 · Cited by 254 · see citing works

Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions

Packard, C. J., Demant, T., Stewart, J., Bedford, D. K., CASLAKE, M. J., Schwertfeger, G., Bedynek, A., Shepherd, J., & Seidel, D. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32065-4 · Cited by 240 · see citing works

Value of Low-Density Lipoprotein Particle Number and Size as Predictors of Coronary Artery Disease in Apparently Healthy Men and Women

El Harchaoui, K., van der Steeg, W. A., Stroes, E. S. G., Kuivenhoven, J. A., Otvos, J. D., Wareham, N. J., Hutten, B. A., Kastelein, J. J. P., Khaw, K.-T., & Boekholdt, S. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.043 · Cited by 239 · see citing works

Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study

Contois, J. H., McNamara, J. R., Lammi‐Keefe, C. J., Wilson, P. W. F., Massov, T., & Schaefer, E. J. (1996) · Clinical Chemistry · doi:10.1093/clinchem/42.4.515 · Cited by 231 · see citing works

Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease.

Eberly, L. E. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1077 · Cited by 226 · see citing works

Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein

Packard, C. J. (2003) · Biochemical Society Transactions · doi:10.1042/bst0311066 · Cited by 225 · see citing works

Trends in Statin Use and Low-Density Lipoprotein Cholesterol Levels Among US Adults: Impact of the 2001 National Cholesterol Education Program Guidelines

Mann, D., Reynolds, K., Smith, D. A., & Muntner, P. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1l181 · Cited by 222 · see citing works

Randomized controlled trial of the effect of n–3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity

Chan, D. C., Watts, G. F., Mori, T. A., Barrett, P. H. R., Redgrave, T. G., & Beilin, L. J. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.2.300 · Cited by 185 · see citing works

Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Small, Dense LDL Particles in Human Plasma

Gazi, I. F., Lourida, E. S., Filippatos, T. D., Tsimihodimos, V., Elisaf, M., & Tselepis, A. D. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.058404 · Cited by 162 · see citing works

Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia

Chan, D. C., Watts, G. F., Barrett, P. H. R., Beilin, L. J., Redgrave, T. G., & Mori, T. A. (2002) · Diabetes · doi:10.2337/diabetes.51.8.2377 · Cited by 160 · see citing works

Influence of n-3 fatty acid supplementation on the endogenous activities of plasma lipases

Harris, W., Lu, G., Rambjør, G., Wõlen, A., Ontko, J., Cheng, Q., & Windsor, S. (1997) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/66.2.254 · Cited by 135 · see citing works

Efficacy of n‐3 polyunsaturated fatty acids after myocardial infarction: Results of GISSI‐prevenzione trial

Marchioli, R., Schweiger, C., Tavazzi, L., & Valagussa, F. (2001) · Lipids · doi:10.1007/s11745-001-0694-8 · Cited by 131 · see citing works

Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses

Calabresi, L., Donati, D., Pazzucconi, F., Sirtori, C. R., & Franceschini, G. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00267-1 · Cited by 104 · see citing works

Dietary fish oil increases conversion of very low density lipoprotein apoprotein B to low density lipoprotein.

Huff, M. W., & Telford, D. E. (1989) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.9.1.58 · Cited by 94 · see citing works

Lipoprotein-Associated Phospholipase A2: An Independent Predictor of Coronary Artery Disease Events in Primary and Secondary Prevention

Anderson, J. L. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.04.015 · Cited by 90 · see citing works

Effects of Adding Prescription Omega-3 Acid Ethyl Esters to Simvastatin (20 mg/day) on Lipids and Lipoprotein Particles in Men and Women With Mixed Dyslipidemia

Maki, K. C., McKenney, J. M., Reeves, M. S., Lubin, B. C., & Dicklin, M. R. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.03.078 · Cited by 81 · see citing works

Postprandial chylomicrons and VLDLs in severe hypertriacylglycerolemia are lowered more effectively than are chylomicron remnants after treatment with n−3 fatty acids

Westphal, S., Orth, M., Ambrosch, A., Osmundsen, K., & Luley, C. H. (2000) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.4.914 · Cited by 79 · see citing works

Dietary factors in the prevention of diabetes mellitus and coronary artery disease associated with the metabolic syndrome

Maki, K. C. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.02.001 · Cited by 71 · see citing works

Effect of dietary fish oil on blood levels of free fatty acids, ketone bodies and triacylglycerol in humans

Dagnelie, P. C., Rietveld, T., Swart, G. R., & Stijnen, T. (1994) · Lipids · doi:10.1007/bf02537089 · Cited by 68 · see citing works

Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A2

Gaubatz, J. W., Gillard, B. K., Massey, J. B., Hoogeveen, R. C., Huang, M. T.-H., Lloyd, E. E., Raya, J. L., Yang, C.-Y., & Pownall, H. J. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600249-jlr200 · Cited by 66 · see citing works

Plasma Apolipoprotein C-III Transport in Centrally Obese Men: Associations with Very Low-Density Lipoprotein Apolipoprotein B and High-Density Lipoprotein Apolipoprotein A-I Metabolism

Chan, D. C., Nguyen, M. N., Watts, G. F., & Barrett, P. H. R. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2676 · Cited by 62 · see citing works

Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy

Ginsberg, H. N. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01489-8 · Cited by 60 · see citing works

Lipoprotein Particle Concentrations May Explain the Absence of Coronary Protection in the Women’s Health Initiative Hormone Trials

Hsia, J. A., Otvos, J. D., Rossouw, J. E., Wu, L., Wassertheil-Smoller, S. W., Hendrix, S. L., Robinson, J. G., Lund, B., & Kuller, L. H. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.170431 · Cited by 55 · see citing works

Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects

Davidson, M. H., Bays, H. E., Stein, E., Maki, K. C., Shalwitz, R. A., & Doyle, R. (2006) · Clinical Cardiology · doi:10.1002/clc.4960290609 · Cited by 51 · see citing works

Effects of purified eicosapentaenoic acid ethyl ester on plasma lipoproteins in primary hypercholesterolemia.

Nozaki, S., Matsuzawa, Y., Hirano, K., Sakai, N., Kubo, M., & Tarui, S. (1992) · PubMed · Cited by 36 · see citing works

Changes in lipoprotein composition in hypertriglyceridemic patients taking cholesterol-free fish oil supplements

Inagaki, M., & Harris, W. S. (1990) · Atherosclerosis · doi:10.1016/0021-9150(90)90045-k · Cited by 26 · see citing works

Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction

Sudhir, K. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.2.153 · Cited by 25 · see citing works

Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)

Ballantyne, C. M., Bays, H. E., Kastelein, J. J., Stein, E., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.05.031 · Cited by 342 · see citing works

Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease

Rosenson, R. S., Davidson, M. H., Hirsh, B. J., Kathiresan, S., & Gaudet, D. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.042 · Cited by 260 · see citing works

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial

Kastelein, J. J. P., Maki, K. C., Susekov, A., Ezhov, M., Nordestgaard, B. G., Machielse, B. N., Kling, D., & Davidson, M. H. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.10.003 · Cited by 233 · see citing works

Omega-3 fatty acids supplementation and oxidative stress parameters: A systematic review and meta-analysis of clinical trials

Heshmati, J., Morvaridzadeh, M., Maroufizadeh, S., Akbari, A., Yavari, M., Amirinejad, A., Maleki‐Hajiagha, A., & Sepidarkish, M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104462 · Cited by 211 · see citing works

Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women

Maki, K. C., Reeves, M. S., Farmer, M. V., Griinari, M., Berge, K., Vik, H., Hubacher, R., & Rains, T. M. (2009) · Nutrition Research · doi:10.1016/j.nutres.2009.09.004 · Cited by 192 · see citing works

Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies

Bays, H. E., Ballantyne, C. M., Braeckman, R. A., Stirtan, W. G., & Soni, P. N. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-012-0002-3 · Cited by 141 · see citing works

Overview of omega-3 Fatty Acid therapies.

Bradberry, J. C., & Hilleman, D. E. (2013) · PubMed Central · Cited by 109 · see citing works

Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)

Bays, H. E., Braeckman, R. A., Ballantyne, C. M., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., & Soni, P. N. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.07.001 · Cited by 94 · see citing works

Omega-3 fatty acids

Davidson, M. H. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000019 · Cited by 87 · see citing works

Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence

Maki, K. C., Bays, H. E., & Dicklin, M. R. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.04.003 · Cited by 83 · see citing works

Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia

Maki, K. C., Bays, H. E., Dicklin, M. R., Johnson, S. L., & Shabbout, M. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.09.001 · Cited by 81 · see citing works

Red blood cell fatty acids and biomarkers of inflammation: A cross-sectional study in a community-based cohort

Fontes, J. D., Rahman, F., Lacey, S., Larson, M. G., Vasan, R. S., Benjamin, E. J., Harris, W. S., & Robins, S. J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.03.043 · Cited by 71 · see citing works

Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study

Brinton, E. A., Ballantyne, C. M., Bays, H. E., Kastelein, J. J., Braeckman, R. A., & Soni, P. N. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-100 · Cited by 70 · see citing works

Bioavailability of long chain omega-3 polyunsaturated fatty acids from phospholipid-rich herring roe oil in men and women with mildly elevated triacylglycerols

Cook, C. M., Hallaråker, H., Sæbø, P. C., Innis, S. M., Kelley, K., Sanoshy, K. D., Berger, A., & Maki, K. C. (2016) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2016.01.007 · Cited by 64 · see citing works

Triglyceride-lowering and anti-inflammatory mechanisms of omega-3 polyunsaturated fatty acids for atherosclerotic cardiovascular risk reduction

Liu, Q. K. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.05.007 · Cited by 65 · see citing works

Science behind the cardio-metabolic benefits of omega-3 polyunsaturated fatty acids: biochemical effects vs . clinical outcomes

Thota, R. N., Ferguson, J. J. A., Abbott, K. A., Dias, C. B., & Garg, M. L. (2018) · Food & Function · doi:10.1039/c8fo00348c · Cited by 60 · see citing works

Effects of Prescription Omega-3-Acid Ethyl Esters on Non—High-Density Lipoprotein Cholesterol When Coadministered With Escalating Doses of Atorvastatin

Bays, H. E., McKenney, J., Maki, K. C., Doyle, R. T., Carter, R. N., & Stein, E. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0397 · Cited by 54 · see citing works

Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial

Dunbar, R. L., Nicholls, S. J., Maki, K. C., Roth, E. M., Orloff, D. G., Curcio, D., Johnson, J., Kling, D., & Davidson, M. H. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0100-8 · Cited by 52 · see citing works

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies

Ballantyne, C. M., Bays, H. E., Philip, S., Doyle, R. T., Braeckman, R. A., Stirtan, W. G., Soni, P. N., & Juliano, R. A. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.005 · Cited by 52 · see citing works

Insights into the cardioprotective properties of n-3 PUFAs against ischemic heart disease via modulation of the innate immune system

Darwesh, A. M., Sosnowski, D. K., Lee, T. Y., Keshavarz-Bahaghighat, H., & Seubert, J. M. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.04.037 · Cited by 49 · see citing works

A new, microalgal DHA- and EPA-containing oil lowers triacylglycerols in adults with mild-to-moderate hypertriglyceridemia

Maki, K. C., Yurko‐Mauro, K., Dicklin, M. R., Schild, A. L., & Geohas, J. G. (2014) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2014.07.012 · Cited by 49 · see citing works

Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials

Sahebkar, A., Simental‐Mendía, L. E., Mikhailidis, D. P., Pirro, M., Banach, M., Sirtori, C. R., & Reiner, Ž. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1511919 · Cited by 47 · see citing works

Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients

Hassan, K., Hassan, S., Hijazi, E. G., & Khazim, K. (2010) · Renal Failure · doi:10.3109/0886022x.2010.510231 · Cited by 46 · see citing works

Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: The omega-3 fatty acids randomized double-blind (ORD) study

Tatsuno, I., Saito, Y., Kudou, K., & Ootake, J. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.01.006 · Cited by 42 · see citing works

Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events

Rubenfire, M., Brook, R. D., & Rosenson, R. S. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.03.024 · Cited by 40 · see citing works

History and future of omega-3 fatty acids in cardiovascular disease

Sperling, L. S., & Nelson, J. R. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1120190 · Cited by 34 · see citing works

Novel developments in omega-3 fatty acid-based strategies

Davidson, M. H., Kling, D. F., & Maki, K. C. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834bd642 · Cited by 32 · see citing works

Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol

Savinova, O. V., Fillaus, K., Harris, W. S., & Shearer, G. C. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.04.793 · Cited by 32 · see citing works

The effect of omega-3 carboxylic acids on apolipoprotein CIII−containing lipoproteins in severe hypertriglyceridemia

Morton, A. M., Furtado, J. D., Lee, J., Amerine, W., Davidson, M. H., & Sacks, F. M. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.09.005 · Cited by 32 · see citing works

Effects of Prescription Omega-3-Acid Ethyl Esters on Fasting Lipid Profile in Subjects With Primary Hypercholesterolemia

Maki, K. C., Lawless, A. L., Kelley, K., Dicklin, M. R., Kaden, V. N., Schild, A. L., Rains, T. M., & Marshall, J. W. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318210fca5 · Cited by 31 · see citing works

Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia

Skulas-Ray, A. C., Alaupovic, P., Kris-Etherton, P. M., & West, S. G. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.12.001 · Cited by 30 · see citing works

Associations between red blood cells fatty acids, desaturases indices and metabolism of platelet activating factor in healthy volunteers

Fragopoulou, E., Detopoulou, P., Alepoudea, E., Nomikos, T., Kalogeropoulos, N., & Antonopoulou, S. (2020) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2020.102234 · Cited by 29 · see citing works

N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study

Ide, K., Koshizaka, M., Tokuyama, H., Tokuyama, T., Ishikawa, T., Maezawa, Y., Takemoto, M., & Yokote, K. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0706-8 · Cited by 27 · see citing works

A porcine gluteus medius muscle genome-wide transcriptome analysis: dietary effects of omega-6 and omega-3 fatty acids on biological mechanisms

Ogłuszka, M., Szostak, A., PAS, M. F. W. T., Poławska, E., Urbański, P., Blicharski, T., Pareek, C. S., Juszczuk‐Kubiak, E., Dunkelberger, J., Horbańczuk, J. O., et al. (2017) · Genes & Nutrition · doi:10.1186/s12263-017-0552-8 · Cited by 25 · see citing works

The nuances of atherogenic dyslipidemia in diabetes: Focus on triglycerides and current management strategies

Manoria, P. C., Chopra, H. K., Parashar, S.-R., Dutta, A. L., Pinto, B., Mullasari, A., & Prajapati, S. (2013) · Indian Heart Journal · doi:10.1016/j.ihj.2013.10.015 · Cited by 24 · see citing works

Baseline Lipoprotein Lipids and Low-Density Lipoprotein Cholesterol Response to Prescription Omega-3 Acid Ethyl Ester Added to Simvastatin Therapy

Maki, K. C., Dicklin, M. R., Davidson, M. H., Doyle, R. T., & Ballantyne, C. M. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.12.063 · Cited by 24 · see citing works

Understanding hypertriglyceridemia in women: clinical impact and management with prescription omega-3-acid ethyl esters

Dayspring, T. D. (2011) · International Journal of Women s Health · doi:10.2147/ijwh.s16702 · Cited by 23 · see citing works

Triglyceride-rich lipoprotein cholesterol (TRL-C): the ugly stepsister of LDL-C

Davidson, M. H. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx741 · Cited by 23 · see citing works

Update on the management of severe hypertriglyceridemia – focus on free fatty acid forms of omega-3

Catapano, A. L., & Pirillo, A. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s67551 · Cited by 22 · see citing works

Association between omega-3 index and blood lipids in older Australians

Ferguson, J. J. A., Veysey, M. J., Lucock, M. D., Niblett, S. H., King, K., MacDonald‐Wicks, L. K., & Garg, M. L. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.09.010 · Cited by 22 · see citing works

Prescription omega-3-acid ethyl esters reduce fasting and postprandial triglycerides and modestly reduce pancreatic β-cell response in subjects with primary hypertriglyceridemia

Maki, K. C., Lawless, A. L., Kelley, K., Dicklin, M. R., Schild, A. L., & Rains, T. M. (2011) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2011.06.005 · Cited by 21 · see citing works

Effects of MAT9001 containing eicosapentaenoic acid and docosapentaenoic acid, compared to eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol, and related variables

Maki, K. C., Bobotas, G., Dicklin, M. R., Huebner, M., & Keane, W. F. (2017) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.10.010 · Cited by 20 · see citing works

The future of n-3 polyunsaturated fatty acid therapy

Davidson, M. H., & Benes, L. B. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000353 · Cited by 18 · see citing works

Triglyceride Lowering Drugs

Feingold, K. R. (2017) · Europe PMC (PubMed Central) · Cited by 18 · see citing works

n-3 andn-6 Fatty acids are independently associated with lipoprotein-associated phospholipase A2in the Multi-Ethnic Study of Atherosclerosis

Steffen, B. T., Steffen, L. M., Liang, S., Tracy, R. P., Jenny, N. S., & Tsai, M. Y. (2013) · British Journal Of Nutrition · doi:10.1017/s0007114513000949 · Cited by 17 · see citing works

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Ethyl-Ester Omega-3 Fatty Acid in Taiwanese Hypertriglyceridemic Patients

Su, T., Hwang, J., Huang, K., Chiang, F., Chien, K., Wang, K., Charng, M., Tsai, W., Lin, L., Vige, R., et al. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.34231 · Cited by 17 · see citing works

The ezetimibe controversy: implications for clinical practice

Khanderia, U., Regal, R. E., Rubenfire, M., & Boyden, T. F. (2011) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944711410099 · Cited by 15 · see citing works

Effects of canola or olive oil on plasma lipids, lipoprotein-associated phospholipase A2 and inflammatory cytokines in patients referred for coronary angiography

Khandouzi, N., Zahedmehr, A., & Nasrollahzadeh, J. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01362-z · Cited by 14 · see citing works

Changes in lipoprotein particle subclasses, standard lipids, and apolipoproteins after supplementation with n-3 or n-6 PUFAs in abdominal obesity: A randomized double-blind crossover study

Grytten, E., Laupsa‐Borge, J., Bohov, P., Bjørndal, B., Strand, E., Skorve, J., Nordrehaug, J. E., Berge, R. K., Rostrup, E., Mellgren, G., et al. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.03.040 · Cited by 14 · see citing works

Hypertriglyceridaemia, Postprandial Lipaemia and Non-HDL Cholesterol

Stefanutti, C., Labbadia, G., & Athyros, V. G. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140620120130 · Cited by 13 · see citing works

Omega-3 index and smoking in patients with acute ST-elevation myocardial infarction taking statins: a case-control study in Korea

Kim, Y., Jeong, D. W., Lee, J. G., Lee, H. C., Lee, S. Y., Kim, Y. J., Yi, Y. H., Park, Y. S., Cho, Y. H., Bae, M. J., et al. (2012) · Lipids in Health and Disease · doi:10.1186/1476-511x-11-43 · Cited by 11 · see citing works

Safety and lipid-altering efficacy of a new omega-3 fatty acid and antioxidant-containing medical food in men and women with elevated triacylglycerols

Maki, K. C., Geohas, J. G., Dicklin, M. R., Huebner, M., & Udani, J. K. (2015) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2015.05.002 · Cited by 11 · see citing works

Maternal Supraphysiological Hypercholesterolemia Is Accompanied by Shifts in the Composition and Anti-Atherogenic Functions of Maternal HDL along with Maternal Cardiovascular Risk Markers at Term of Pregnancy

Cantin, C., Morales, A., Serra, R., Illanes, S. E., & Leiva, A. (2023) · Antioxidants · doi:10.3390/antiox12101804 · Cited by 9 · see citing works

Effect of TAK ‐085 on Low‐density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double‐blind Randomized Clinical Study

Tatsuno, I., Kudou, K., & Kagawa, T. (2015) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12146 · Cited by 7 · see citing works

Pathophysiology and Management of Dyslipidemias Associated with Insulin-Resistant States

Maki, K. C., Benes, L. B., & Dicklin, M. R. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_16 · Cited by 5 · see citing works

Impact of omega-3 supplementation on lipoprotein-associated phospholipase A2 mass and activity: A systematic review and meta-analysis of randomized controlled trials

Simental-Mendía, L. E., Simental-Mendía, M., Barragán‐Zuñiga, L. J., & Aguillón-Marín, P. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.12.013 · Cited by 4 · see citing works

n-3 Polyunsaturated Fatty Acid Supplementation Affects Oxidative Stress Marker Levels in Patients with Type II Intestinal Failure: A Randomized Double Blind Trial

Flores‐López, A., Guevara‐Cruz, M., Ávila-Nava, A., Garay, A. G. G., González-Salazar, L. E., Reyes-Ramírez, A. L., Pedraza‐Chaverrí, J., Medina‐Campos, O. N., Vera, I., Reyes‐García, G., et al. (2023) · Antioxidants · doi:10.3390/antiox12081493 · Cited by 4 · see citing works

Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs

Takata, K., & Nicholls, S. J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0312-1 · Cited by 4 · see citing works

Does Consumption of Omega-3 Polyunsaturated Fatty Acids Affect Lipid Profile and Fasting Blood Glucose in Patients With Traumatic Spinal Cord Injury? A Double-Blinded Randomized Clinical Trial

Sabour, H., Norouzi‐Javidan, A., Latifi, S., Shakeri, H., Arman, F., Larijani, B. A., Shidfar, F., Heshmat, R., Razavi, S.-H. E., & Vafa, M. (2015) · Topics in Clinical Nutrition · doi:10.1097/tin.0000000000000051 · Cited by 3 · see citing works

Omega-3 Polyunsaturated Fatty Acids and Hyperlipidaemias

Ferguson, J. J. A., Dias, C. B., & Garg, M. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-40458-5_6 · Cited by 2 · see citing works

Targeting Enzymatic Pathways with Marine‐Derived Clinical Agents

Pereira, R. B., Dasari, R., Lefranc, F., Kornienko, A., Robert Kiss, A., & Gomes, N. G. M. (2017) · doi:10.1002/9783527805921.ch10 · Cited by 2 · see citing works

The Role of Omega-3 Fatty Acids in Dyslipidemias

Brandt, E. J., & Davidson, M. H. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_5 · Cited by 1 · see citing works

Effect of Omega-3 Fatty Acids Supplementation on Homocysteine Level in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis

Gholipourshahraki, T., Vahdat, S., Seirafian, S., Pourfarzam, M., & Badri, S. (2022) · Journal of Research in Pharmacy Practice · doi:10.4103/jrpp.jrpp_67_22 · Cited by 1 · see citing works

Fish/Fish Oil Intake and Inflammatory Biomarkers, Endothelial Function

Steffen, B. T., & Steffen, L. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802844-5.00017-8 · Cited by 1 · see citing works

Advances in Hypercholesterolemia

Pirillo, A., Norata, G. D., & Catapano, A. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12435-7 · Cited by 1 · see citing works

Therapy to Manage Low High-Density Lipoprotein Cholesterol and Elevated Triglycerides

Davidson, M. H. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00025-4

N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease

Barringer, T. A., Harris, W. S., Fleming, J. A., & Kris‐Etherton, P. M. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_21

Role of Lipoprotein-Associated Phospholipase A2 in Vascular Disease

Rosenson, R. S., & Stafforini, D. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00013-x

Omega-3 Fatty Acids

Harris, W. S., & Jacobson, T. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00026-8

Omega-3 supplementation and Lp-PLA2: The importance of the lipoprotein carrier context

Wu, Y. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.01.010

Response to the letter regarding "Omega-3 supplementation and Lp-PLA2: The importance of the lipoprotein carrier context"

Simental‐Mendía, L. E., Simental-Mendía, M. A., Barragán‐Zuñiga, L. J., & Aguillón-Marín, P. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.01.019

Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia

Maki, K. C., Bays, H. E., Dicklin, M. R., Johnson, S. L., & Shabbout, M. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.09.001 · Cited by 81 · see citing works

Effects of Adding Prescription Omega-3 Acid Ethyl Esters to Simvastatin (20 mg/day) on Lipids and Lipoprotein Particles in Men and Women With Mixed Dyslipidemia

Maki, K. C., McKenney, J. M., Reeves, M. S., Lubin, B. C., & Dicklin, M. R. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.03.078 · Cited by 81 · see citing works

Lipid effects of prescription omega‐3‐acid ethyl esters plus simvastatin in subjects with hypertriglyceridemia

Maki, K. C., McKenney, J. M., Lubin, B. C., & Reeves, M. S. (2008) · The FASEB Journal · doi:10.1096/fasebj.22.1_supplement.147.8

Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial

Dunbar, R. L., Nicholls, S. J., Maki, K. C., Roth, E. M., Orloff, D. G., Curcio, D., Johnson, J., Kling, D., & Davidson, M. H. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0100-8 · Cited by 52 · see citing works

Baseline Lipoprotein Lipids and Low-Density Lipoprotein Cholesterol Response to Prescription Omega-3 Acid Ethyl Ester Added to Simvastatin Therapy

Maki, K. C., Dicklin, M. R., Davidson, M. H., Doyle, R. T., & Ballantyne, C. M. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.12.063 · Cited by 24 · see citing works